WebDec 1, 2015 · NovaLead Pharma announced a potential breakthrough in the treatment of diabetic foot ulcers (DFU). The recently concluded global Phase I/II clinical trial of its … WebApr 1, 2024 · The conclusions of the startup, which is backed by Tata Capital Healthcare Fund, are based on a study of 2,100 approved drugs and 30 potential viral and human targets.

Venous Leg Ulcers - Pipeline Insight, 2024 - Research and Markets

WebNov 4, 2015 · With the discovery of Galnobax, NovaLead has established an existing generic drug base as a potential source for novel therapeutics for hard to treat diseases. The drug has already received patents in all regulated markets namely USA, EU and Japan as well as in emerging markets like India and China. WebNovalead Pharma has been selected by Frost & Sullivan, leading global industry tracking firm as Best Technology Company in Drug Repositioning for the Year 2024. The award was received by our CEO Mr. Supreet … imperial brands 245 hammersmith road

NovaLead Pharma - Crunchbase Company Profile

Web1 Department of Endocrinology, Post Graduate Institute of Medical Education and research (PGIMER), Chandigarh, India. 2 Department of Drug Research, NovaLead Pharma Pvt. Ltd., Pune, India. 3 Department of Surgery, VA New England Health Care Division, Providence, Rhode Island, USA. WebPreviously in 2015, NovaLead Pharma also received the Best Innovation Company BIRAC award from DBT. Mr. Supreet Deshpande’s interview conducted by Frost & Sullivan will be shared in coming days. WebDec 1, 2015 · NovaLead Pharma announced a potential breakthrough in the treatment of diabetic foot ulcers (DFU). The recently concluded global Phase I/II clinical trial of its repositioned investigational drug ... lit blow torch